RhumbLine Advisers
MED icon

RhumbLine Advisers’s Medifast MED Stock Holding History

RhumbLine Advisers’s Portfolio MED Stock Details MED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68.8K Sell
6,485
-8,117
-56% -$93.6K ﹤0.01% 3623
2026
Q1 		$149K Sell
14,602
-207
-1% -$2.23K ﹤0.01% 3247
2025
Q4 		$158K Sell
14,809
-2,968
-17% -$35.5K ﹤0.01% 3286
2025
Q3 		$243K Sell
17,777
-679
-4% -$9.48K ﹤0.01% 3123
2025
Q2 		$259K Sell
18,456
-720
-4% -$9.46K ﹤0.01% 3086
2025
Q1 		$258K Sell
19,176
-662
-3% -$9.94K ﹤0.01% 2976
2024
Q4 		$350K Buy
19,838
+412
+2% +$7.64K ﹤0.01% 2896
2024
Q3 		$372K Sell
19,426
-10,078
-34% -$194K ﹤0.01% 2905
2024
Q2 		$644K Sell
29,504
-14,646
-33% -$390K ﹤0.01% 2488
2024
Q1 		$1.69M Buy
44,150
+4,544
+11% +$220K ﹤0.01% 1984
2023
Q4 		$2.66M Buy
39,606
+649
+2% +$45.2K ﹤0.01% 1765
2023
Q3 		$2.92M Sell
38,957
-1,289
-3% -$114K ﹤0.01% 1658
2023
Q2 		$3.71M Buy
40,246
+204
+0.5% +$18.2K ﹤0.01% 1561
2023
Q1 		$4.15M Buy
40,042
+3,756
+10% +$416K 0.01% 1431
2022
Q4 		$4.19M Sell
36,286
-123
-0.3% -$14.3K 0.01% 1384
2022
Q3 		$3.94M Buy
36,409
+2,724
+8% +$390K 0.01% 1369
2022
Q2 		$6.08M Buy
33,685
+1,171
+4% +$210K 0.01% 1147
2022
Q1 		$5.55M Buy
32,514
+2,487
+8% +$469K 0.01% 1246
2021
Q4 		$6.29M Sell
30,027
-176
-0.6% -$36.4K 0.01% 1235
2021
Q3 		$5.82M Sell
30,203
-4,113
-12% -$1.01M 0.01% 1269
2021
Q2 		$9.71M Buy
34,316
+98
+0.3% +$26.6K 0.01% 1021
2021
Q1 		$7.25M Buy
34,218
+1,951
+6% +$467K 0.01% 1195
2020
Q4 		$6.33M Buy
32,267
+839
+3% +$148K 0.01% 1220
2020
Q3 		$5.17M Sell
31,428
-3,681
-10% -$606K 0.01% 1147
2020
Q2 		$4.87M Sell
35,109
-2,162
-6% -$199K 0.01% 1230
2020
Q1 		$2.33M Buy
37,271
+266
+0.7% +$24.2K ﹤0.01% 1467
2019
Q4 		$4.05M Buy
37,005
+2,070
+6% +$200K 0.01% 1378
2019
Q3 		$3.62M Sell
34,935
-104
-0.3% -$11.2K 0.01% 1369
2019
Q2 		$4.5M Buy
35,039
+581
+2% +$80.7K 0.01% 1260
2019
Q1 		$4.39M Buy
34,458
+352
+1% +$44.6K 0.01% 1254
2018
Q4 		$4.26M Buy
34,106
+6,132
+22% +$1.05M 0.01% 1206
2018
Q3 		$6.2M Buy
27,974
+927
+3% +$188K 0.01% 967
2018
Q2 		$4.33M Buy
27,047
+1,808
+7% +$231K 0.01% 1195
2018
Q1 		$2.36M Buy
25,239
+337
+1% +$25.2K ﹤0.01% 1507
2017
Q4 		$1.74M Buy
24,902
+3,071
+14% +$204K ﹤0.01% 1700
2017
Q3 		$1.3M Buy
21,831
+347
+2% +$17.3K ﹤0.01% 1852
2017
Q2 		$891K Sell
21,484
-50
-0.2% -$2.17K ﹤0.01% 2005
2017
Q1 		$955K Buy
21,534
+6,314
+41% +$272K ﹤0.01% 1947
2016
Q4 		$634K Buy
15,220
+498
+3% +$20.1K ﹤0.01% 2105
2016
Q3 		$556K Buy
14,722
+1,060
+8% +$38K ﹤0.01% 2133
2016
Q2 		$455K Buy
13,662
+200
+1% +$6.45K ﹤0.01% 2252
2016
Q1 		$406K Sell
13,462
-15
-0.1% -$438 ﹤0.01% 2359
2015
Q4 		$409K Buy
13,477
+705
+6% +$21K ﹤0.01% 2380
2015
Q3 		$343K Buy
12,772
+184
+1% +$5.36K ﹤0.01% 2456
2015
Q2 		$407K Sell
12,588
-2,235
-15% -$70.9K ﹤0.01% 2466
2015
Q1 		$444K Buy
14,823
+1,350
+10% +$42.9K ﹤0.01% 2363
2014
Q4 		$452K Sell
13,473
-405
-3% -$12.6K ﹤0.01% 2332
2014
Q3 		$456K Sell
13,878
-50
-0.4% -$1.53K ﹤0.01% 2266
2014
Q2 		$424K Sell
13,928
-1,312
-9% -$40.9K ﹤0.01% 2373
2014
Q1 		$443K Sell
15,240
-670
-4% -$17.9K ﹤0.01% 2297
2013
Q4 		$416K Sell
15,910
-160
-1% -$4.1K ﹤0.01% 2367
2013
Q3 		$432K Sell
16,070
-434
-3% -$11.6K ﹤0.01% 2313
2013
Q2 		$425K Buy
+16,504
New +$433K ﹤0.01% 2374

Other funds holding MED

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCP
Steamboat Capital Partners Rye, New York $468M AUM 80.81% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RhumbLine Advisers's MED Position: Q2 2026 in Review

RhumbLine Advisers reduced its Medifast (MED) stake by 56% in Q2 2026, selling an estimated $93.6K and leaving 6,485 shares worth $68.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3623.

RhumbLine Advisers first reported a position in MED in Q2 2013 and has held it in 53 quarters since. The position peaked at $9.71M in Q2 2021. 102 funds tracked by Wall St. Rank hold MED as of Q2 2026.

  • RhumbLine Advisers held 6,485 shares of Medifast worth $68.8K as of Q2 2026.
  • RhumbLine Advisers sold 8,117 Medifast shares in Q2 2026, an estimated $93.6K.
  • Medifast made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3623 holding.
  • RhumbLine Advisers first reported a position in Medifast in Q2 2013 and has held it in 53 quarters since.
  • RhumbLine Advisers's Medifast position peaked at $9.71M in Q2 2021.
  • 102 funds tracked by Wall St. Rank held Medifast as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.